Provided by Tiger Fintech (Singapore) Pte. Ltd.

Sight Sciences, Inc.

2.99
+0.23008.33%
Post-market: 2.990.00000.00%16:30 EDT
Volume:165.02K
Turnover:477.57K
Market Cap:153.48M
PE:-2.91
High:3.00
Open:2.81
Low:2.78
Close:2.76
Loading ...

UBS Adjusts Price Target on Sight Sciences to $5 From $5.50, Keeps Buy Rating

MT Newswires Live
·
27 Jan

Sight Sciences price target lowered to $5 from $5.50 at UBS

TIPRANKS
·
26 Jan

Promising US Penny Stocks To Consider In January 2025

Simply Wall St.
·
25 Jan

Sight Sciences Inc : Morgan Stanley Cuts Target Price to $3.00 From $4.00

THOMSON REUTERS
·
23 Jan

Citi Remains a Hold on Sight Sciences (SGHT)

TIPRANKS
·
17 Jan

Sight Sciences price target lowered to $3 from $5 at Lake Street

TIPRANKS
·
15 Jan

Stifel Nicolaus Sticks to Their Buy Rating for Sight Sciences (SGHT)

TIPRANKS
·
15 Jan

Lake Street Sticks to Its Hold Rating for Sight Sciences (SGHT)

TIPRANKS
·
14 Jan

Sight Sciences sees Q4 revenue $18.9M-19.1M, consensus $20.29M

TIPRANKS
·
14 Jan

Sight Sciences Announces Preliminary Q4 2024 Revenue Of $18.9M-$19.1M; Surgical Glaucoma Revenue Up 9%; FY24 Revenue $79.7M-$79.9M, Surgical Glaucoma Up 2%

Benzinga
·
14 Jan

Sight Sciences Inc: Q4 Total REV Is Expected to Be in the Range of $18.9 Mln to $19.1 Mln

THOMSON REUTERS
·
14 Jan

Sight Sciences Announces Preliminary, Unaudited Fourth Quarter and Full Year 2024 Financial Highlights

THOMSON REUTERS
·
14 Jan

Sight Sciences Inc Q4 REV View $20.3 Mln -- Lseg Ibes Data

THOMSON REUTERS
·
14 Jan

Sight Sciences Reports Positive OMNI Surgical System Data From 36-Month Study

MT Newswires Live
·
08 Jan

Sight Sciences study demonstrates benefits of OMNI system for managing POAG

TIPRANKS
·
08 Jan

Sight Sciences Announces Real-World 36-Month Study Confirming Long-Term Effectiveness of Standalone OMNI Surgical System in Managing Primary Open-Angle Glaucoma

GlobeNewswire
·
08 Jan

Lake Street Issues a Hold Rating on Sight Sciences (SGHT)

TIPRANKS
·
21 Dec 2024

Sight Sciences' TearCare Treatment for Dry Eye Disease to Generate Cost Savings Versus Existing Prescribed Medications

MT Newswires Live
·
20 Dec 2024

Sight Sciences does BIA of TearCare to treat MGD-associated DED in US

TIPRANKS
·
20 Dec 2024

Sight Sciences Announces the Results of a Budget Impact Analysis for its TearCare® System for the Treatment of Meibomian Gland Disease (“MGD”) Showing Cost Savings Over Existing Reimbursed Treatment Options

GlobeNewswire
·
20 Dec 2024